13 research outputs found

    Effects of Calcium Soaps from Palm, Canola and Safflower Oils on Dry Matter Intake, Nutrient Digestibility, Milk Production, and Milk Composition in Dairy Goats

    Get PDF
    Articulo estudio en cabras suplementadas con jabones de calcioThis study determined the e ect of protected dietary oils on dry matter intake (DMI), digestibility and milk production in dairy goats. Nine Saanen goats were used in a 3 3 Latin square design with three periods of 25 days. A basal diet based on barley hay and corn silage was supplemented with 2.7% DM of calcium soaps of either palm (PO), canola (CO) or sa ower (SO) oils. Data for dry matter intake, nutrient digestibility and milk production was analyzed using the general linear model (GLM) procedure of SAS. Gas production data was analyzed using the procedure of non-linear regression analysis (PROC NLIN) from SAS. Nutrient intakes were not a ected by treatments. However, compared with CO, the digestibility of dry matter (653 vs. 552 and 588 g/kg), organic matter (663 vs. 559 and 606 g/kg) and neutral detergent fiber (616 vs. 460 and 510 g/kg) were lowered (p < 0.001) by SO and PO. Compared with CO, in vitro gas production increased (p < 0.001) in PO and SO (174 vs. 201 and 206 mL gas/g incubated DM). Compared with PO and CO, milk production increased (p < 0.001) with SO (0.88 and 0.95 vs. 1.10 kg/d, respectively). With regard to PO and SO, CO decreased fat (34 and 35 vs. 32 g/d) and protein (35 and 38 vs. 30 g/d) in milk. In conclusion, compared to the traditional use of calcium soaps manufactured from PO, protected SO resulted in increased milk yield without negative e ects on digestibility and nutrient intake.This research was funded by Universidad Autónoma del Estado de México (Project ID UAEMex 3060-2011 and UAEMex4974/2020)

    Myasthenia gravis and pregnancy: clinical implications and neonatal outcome

    Get PDF
    BACKGROUND: The myasthenia gravis is twice as common in women as in men and frequently affects young women in the second and third decades of life, overlapping with the childbearing years. Generally, during pregnancy in one third of patients the disease exacerbates, whereas in two thirds it remains clinically unchanged. Complete remission can occur in some patients. METHODS: To describe the clinical course, delivery and neonatal outcome of 18 pregnant women with the diagnosis of myasthenia gravis. Retrospective chart review of pregnant patients with myasthenia gravis, followed at the National Institute of Perinatology in Mexico City over an 8-year period. Data was abstracted from the medical records on the clinical course during pregnancy, delivery and neonatal outcome. RESULTS: From January 1, 1996 to December 31, 2003 18 patients with myasthenia gravis were identified and included in the study. The mean ± SD maternal age was 27.4 ± 4.0 years. During pregnancy 2 women (11%) had an improvement in the clinical symptoms of myasthenia gravis, 7 women (39%) had clinical worsening of the condition of 9 other patients (50%) remained clinically unchanged. Nine patients delivered vaginally, 8 delivered by cesarean section and 1 pregnancy ended in fetal loss. Seventeen infants were born at mean ± SD gestational age of 37.5 ± 3.0 weeks and a mean birth weight of 2710 ± 73 g. Only one infant presented with transient neonatal myasthenia gravis. No congenital anomalies were identified in any of the newborns. CONCLUSIONS: The clinical course of myasthenia gravis during pregnancy is variable, with a significant proportion of patients experiencing worsening of the clinical symptoms. However, neonatal transient myasthenia was uncommon in our patient population

    Factors associated with therapy noncompliance in type-2 diabetes patients

    No full text
    Objetivo. Identificar la frecuencia y factores asociados al incumplimiento terapéutico en pacientes con diabetes mellitus tipo 2. Material y métodos. Se llevó a cabo un estudio transversal en cuatro clínicas y hospitales de la Ciudad de México, en 79 pacientes con diabetes mellitus tipo 2. Se recolectaron datos sobre el cumplimiento terapéutico, para lo cual se visitó el domicilio de los sujetos de estudio entre marzo de 1998 y agosto de 1999, con el fin de contar los medicamentos. Se definió cumplimiento cuando el paciente administró correctamente 80% de las pastillas o de la dosis de insulina que le correspondía. Se midió el grado de cumplimiento para cada una de las medidas terapéuticas (dieta, ejercicio y asistencia a citas). Resultados. La edad promedio del grupo fue de 59 años (DE=11 años); 58 pacientes (73%) fueron del sexo femenino. La frecuencia de incumplimiento global fue de 39%. La frecuencia de incumplimiento en el grupo donde se pudo llevar a cabo el conteo de medicamentos fue 62% para la dieta, 85% para el ejercicio, 17% para la administración de hipoglucemiantes, 13% para la aplicación de insulina y 3% para la asistencia a citas. Sólo la asociación de incumplimiento con la presencia de hipertensión arterial sistémica más obesidad fue estadísticamente significativa (RM= 4.58, IC 95%= 1.0-22.4, p= 0.02). Conclusiones. La frecuencia de incumplimiento fue muy alta, especialmente en lo que se refiere a la dieta y al ejercicio. El texto completo en inglés de este artículo también está disponible en: http://www.insp.mx/salud/index.htm

    Factors associated with therapy noncompliance in type-2 diabetes patients

    No full text
    OBJECTIVE: To identify the frequency and factors associated with therapy noncompliance in type-2 diabetes mellitus patients. MATERIAL AND METHODS: A cross-sectional study was carried out in 79 patients with type-2 diabetes mellitus seen in major hospitals of Mexico City. Patients were visited at home, from March 1998 to August 1999, to measure compliance with prescribed therapy. Complying patients were defined as those taking at least 80% of their pills or 80% of their corresponding insulin dose. The degree of compliance with therapy components (diet, amount of exercise, and keeping appointments) was measured. RESULTS: The average age of study subjects was 59 years (SD 11 years); 73% (n=58) were female subjects. The overall frequency of noncompliance was 39%. Noncompliance rates were: 62% for dietary recommendations, 85% for exercise, 17% for intake of oral hypoglycemic medication, 13% for insulin application, and 3% for appointment keeping. Hypertension plus obesity was the only factor significantly associated with noncompliance (OR 4.58, CI 95% 1.0, 22.4, p=0.02). CONCLUSIONS: The frequency of therapy noncompliance was very high, especially for diet and exercise

    Myasthenia gravis and pregnancy: clinical implications and neonatal outcome

    No full text
    Abstract Background The myasthenia gravis is twice as common in women as in men and frequently affects young women in the second and third decades of life, overlapping with the childbearing years. Generally, during pregnancy in one third of patients the disease exacerbates, whereas in two thirds it remains clinically unchanged. Complete remission can occur in some patients. Methods To describe the clinical course, delivery and neonatal outcome of 18 pregnant women with the diagnosis of myasthenia gravis. Retrospective chart review of pregnant patients with myasthenia gravis, followed at the National Institute of Perinatology in Mexico City over an 8-year period. Data was abstracted from the medical records on the clinical course during pregnancy, delivery and neonatal outcome. Results From January 1, 1996 to December 31, 2003 18 patients with myasthenia gravis were identified and included in the study. The mean ± SD maternal age was 27.4 ± 4.0 years. During pregnancy 2 women (11%) had an improvement in the clinical symptoms of myasthenia gravis, 7 women (39%) had clinical worsening of the condition of 9 other patients (50%) remained clinically unchanged. Nine patients delivered vaginally, 8 delivered by cesarean section and 1 pregnancy ended in fetal loss. Seventeen infants were born at mean ± SD gestational age of 37.5 ± 3.0 weeks and a mean birth weight of 2710 ± 73 g. Only one infant presented with transient neonatal myasthenia gravis. No congenital anomalies were identified in any of the newborns. Conclusions The clinical course of myasthenia gravis during pregnancy is variable, with a significant proportion of patients experiencing worsening of the clinical symptoms. However, neonatal transient myasthenia was uncommon in our patient population.</p

    Impacto nutricio del consumo de una leche entera adicionada con vitaminas y minerales en niños Nutritional impact of a full strenght milk with added vitamins and minerals in children

    No full text
    OBJETIVO: Determinar el impacto nutricio del consumo de leche entera fortificada con vitaminas y minerales en niños. MATERIAL Y MÉTODOS: Se hizo un estudio prospectivo, longitudinal, en 227 niños de entre 8 a 60 meses de edad. Se ofreció a los menores 500 ml diarios de leche entera fortificada por 90 días. Se registró ingestión, aceptación, peso, talla, hemoglobina (Hb), hierro (Fe), vitamina B12 y folatos séricos. El análisis estadístico se realizó con medidas de tendencia central y dispersión en variables dimensionales utilizando prueba t de Student para comparación de promedios y ji² para variables nominales. RESULTADOS: Al inicio de la suplementación 45 niños estaban desnutridos, y 36, anémicos. Al final de la misma estas cifras disminuyeron: 35 desnutridos (pOBJECTIVE: To evaluate the nutritional impact of the ingestion of a fortified whole milk in children. MATERIAL AND METHODS: Prospective, longitudinal assay in 227 children aged 8-60 months. Intervention: Daily consumption of 500 ml of fortified milk during 90 days. We registered milk acceptance and assessed weight, height; hemoglobin, serum iron, vitamin B12, and folic acid, at the beginning and the end of the study. Statistical evaluation were done with central and dispersion indices in the dimensional variables, using Student's t test and chi² test for compare nominal variables at initial and the end of the study. RESULTS: At admission, 45 children were malnourished and 36 were anemic. At the end of the supplementation period there was a reduction to 35 malnourished (p< 0.21) and 18 anemic (p< 0.01). Anthropometric weight/height score in Z at the beginning and end of the study (x±S.D) were -0.35±0.88 vs -0.14±9 (p< 0.01); Hb g/dl: 11±1.3 vs 11.9±1.9 (p< 0.001), Iron mg/dl: 108±44 vs 115±31 (p= 0.06) and vitamin B12 pg/ml: 649±494 to 1053±854 (p< 0.001). The milk was well tolerated and widely accepted. CONCLUSIONS: The consumption of a fortified whole milk during 90 days improved significantly the nutritional status of the children, the weight for height Z score, the plasma level of vitamin B12 and Hb, and decreased the number of anemic and malnourished children
    corecore